Alpha Teknova Inc(TKNO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 5:42 PM ET (Korea 10/29 06:42)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.31 | Insider Own | 79.65% | Shs Outstand | 53.7M | Perf Week | 34.36% |
| Market Cap | 0.42B | Forward P/E | - | EPS next Y | 14.09% | Insider Trans | - | Shs Float | 10.9M | Perf Month | -13.44% |
| Enterprise Value | 0.43B | PEG | - | EPS next Q | -0.07 | Inst Own | 16.94% | Short Float | 15.09% | Perf Quarter | 55.64% |
| Income | -0.02B | P/S | 9.66 | EPS this Y | 5.93% | Inst Trans | 3.92% | Short Ratio | 4.31 | Perf Half Y | 143.34% |
| Sales | 0.04B | P/B | 6.74 | EPS next 5Y | 15.57% | ROA | -16.25% | Short Interest | 1.65M | Perf YTD | 106.84% |
| Book/sh | 1.17 | P/C | 24.2 | EPS past 3/5Y | 42.42% - | ROE | -24.19% | 52W High | -17.09% ($9.48) | Perf Year | 46.1% |
| Cash/sh | 0.32 | P/FCF | - | Sales past 3/5Y | -0.73% 5.3% | ROIC | -19.04% | 52W Low | 311.52% ($1.91) | Perf 3Y | 293% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.08% | Gross Margin | 31.97% | Volatility(W/M) | 12.35% 7.77% | Perf 5Y | -65.83% |
| Dividend TTM | - | EV/Sales | 9.88 | Sales Y/Y TTM | 12.27% | Oper. Margin | -35.08% | ATR (14) | 0.67 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.48 | EPS Q/Q | 11.53% | Profit Margin | -38.37% | RSI (14) | 53.34 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.49 | Sales Q/Q | 18.45% | SMA20 | 1.32% ($7.76) | Beta | 0.94 | Target Price | $9.67 |
| Payout | - | Debt/Eq | 0.44 | Earnings | 2026/11/4 | SMA50 | 2.24% ($7.69) | Rel Volume | 2.48 | Prev Close | $7.11 |
| Employees | 158 | LT Debt/Eq | 0.41 | EPS/Sales Surpr. | 28.83% 11.26% | SMA200 | 62.15% ($4.85) | Avg Volume(3M) | 0.38M | Price | $7.86 |
| IPO | 2021/6/25 | Option/Short | Yes/Yes | Trades | 5461 | Volume | 950,823 | Change | 10.55% |
🧪 This is a US specialty reagent manufacturer that supplies custom life-science reagents and media used in cell and gene therapy as well as new drug research and production. Headquartered in the US, it has built a broad base of early-stage biotech customers by leveraging fast delivery and small-batch custom manufacturing as its competitive edge, and is classified as a micro-cap stock.
Over the past 1 year, on the higher side
17% below its 1-year high.
Traded more than usual. That is 248% of its average volume.
Next earnings report: November 4
7 days to go.
TKNO has a sound balance sheet but weak earning power
Of every $100 in sales, $35.08 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $966. Peers typically go for $154.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -65.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 16.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #41 of 83 in the industry
Based on market cap of $422M.
EOLS#39 Evolus Inc $504M PER - 
KMDA#40 Kamada Ltd $462M PER 21.0 TKNO#41 Alpha Teknova Inc $422M PER - 
TLRY#42 Tilray Brands Inc $398M PER - 
EBS#43 Emergent Biosolutions Inc $364M PER - 
FAQ
What kind of company is TKNO?
TKNO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TKNO?
The market cap of TKNO is approximately $422M, ranking 3,300 within its sector.
What is the 52-week high and low for TKNO?
TKNO has recorded a 52-week high of $9.48 and a low of $1.91.
